300 related articles for article (PubMed ID: 23989978)
1. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
3. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).
Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA
Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532
[TBL] [Abstract][Full Text] [Related]
5. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
6. Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy.
Jiang X; Li H; Zhao P; Xie J; Khabele D; Xu J; Gore JC
Neoplasia; 2016 Jun; 18(6):387-97. PubMed ID: 27292027
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models.
Izbicka E; Campos D; Marty J; Carrizales G; Mangold G; Tolcher A
Anticancer Res; 2006; 26(3A):1983-8. PubMed ID: 16827133
[TBL] [Abstract][Full Text] [Related]
8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
9. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
11. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
13. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
[TBL] [Abstract][Full Text] [Related]
15. Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.
Chatterjee M; Ben-Josef E; Robb R; Vedaie M; Seum S; Thirumoorthy K; Palanichamy K; Harbrecht M; Chakravarti A; Williams TM
Cancer Res; 2017 Nov; 77(21):5925-5937. PubMed ID: 28923854
[TBL] [Abstract][Full Text] [Related]
16. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
[TBL] [Abstract][Full Text] [Related]
17. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
18. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
[TBL] [Abstract][Full Text] [Related]
19. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
